BPC 10mg + TB 10mg
Preclinical — Animal / cell-model data onlyWhat it is
A higher-strength blend of BPC-157 and TB-500. Evidence for each component is largely preclinical.
A higher-strength single-vial blend of BPC-157 and TB-500 (10 mg of each).
Research context
Studied in relation to:
- Combined tissue-repair research (animal)
Points in its favour in the literature:
- Higher-strength recovery blend
Caveats and unknowns:
- Preclinical evidence base
- Unlicensed for human use
- Prohibited in sport
Handling & reference data
Route in published researchSubcutaneous injection is the route most commonly described in the research literature.
Published clinical / research context (not instructions)Follows the two components; see the BPC-157 and TB-500 profiles.
Storage (lyophilised)Lyophilised (freeze-dried) powder: refrigerate at 2–8 °C short-term, or freeze at −20 °C or below for long-term storage. Keep sealed and out of light.
Reconstituted solutionOnce reconstituted: keep refrigerated (2–8 °C), protect from light, do not freeze. With bacteriostatic water, commonly used within ~4 weeks; with plain sterile water, within ~24–48 h.
Worked reconstitution example (arithmetic only)e.g. 20 mg total (10 mg + 10 mg) + 2 mL → 10 mg/mL.
Available research formats
| Strength | SKU |
|---|---|
| 20mg | BB20 |
Current pricing (THB with USD/GBP conversion) is shown live in the catalogue, which also has a transparent U-100 reconstitution calculator.